Sungjoon Park, Doyeon Hwang, Jeehoon Kang, Jung-Kyu Han, Han-Mo Yang, Kyung Woo Park, Hyun-Jae Kang, Bon-Kwon Koo, Jin-Man Cho, Byung-Ryul Cho, Sung Gyun Ahn, Seok-Min Kang, Jung-Hoon Sung, Ung Kim, Namho Lee, Hyo-Soo Kim
BACKGROUND: Hypertension and dyslipidemia significantly contribute to cardiovascular disease development. Their coexistence poses challenges in managing multiple medications, influencing treatment adherence. OBJECTIVE: This study aimed to assess the efficacy and safety of a combined treatment approach using a fixed-dose combination therapy. METHODS: This multicenter, 8-week, randomized, double-blind, Phase IV trial was named Telmisartan/Amlodipine/Rosuvastatin from Samjin Pharmaceuticals and evaluated the efficacy and safety of fixed-dose combination treatment in patients with essential hypertension and dyslipidemia...
2024: Current Therapeutic Research, Clinical and Experimental